TG-2349

· TaiGen Biotechnology Co., Ltd.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for TG-2349, covering 2014-12-19 to 2021-02-18. Get the full timeline:

Most recent: Clinical Trial Update: To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients [Phase 2]

See pricing